Tango Therapeutics, Inc. (NASDAQ:TNGX) Director Purchases $37,800.00 in Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) Director Mace Rothenberg acquired 10,000 shares of Tango Therapeutics stock in a transaction on Monday, November 18th. The stock was purchased at an average price of $3.78 per share, with a total value of $37,800.00. Following the purchase, the director now owns 31,250 shares of the company’s stock, valued at $118,125. The trade was a 47.06 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Mace Rothenberg also recently made the following trade(s):

• On Thursday, November 14th, Mace Rothenberg acquired 10,000 shares of Tango Therapeutics stock. The shares were bought at an average cost of $3.62 per share, with a total value of $36,200.00.

Tango Therapeutics Trading Down 6.5 %

Shares of NASDAQ:TNGX traded down $0.25 on Monday, hitting $3.60. The company had a trading volume of 1,654,812 shares, compared to its average volume of 987,487. The company has a market cap of $386.71 million, a PE ratio of -3.02 and a beta of 0.88. The business has a 50 day moving average of $6.65 and a 200 day moving average of $8.15. Tango Therapeutics, Inc. has a 52-week low of $2.70 and a 52-week high of $13.01.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Wedbush increased their price target on shares of Tango Therapeutics from $11.00 to $13.00 and gave the stock an “outperform” rating in a report on Thursday, August 8th. Guggenheim lowered their target price on shares of Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. B. Riley reduced their price objective on Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating for the company in a report on Monday, November 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $13.00 target price on shares of Tango Therapeutics in a report on Friday, November 8th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $13.14.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD increased its stake in shares of Tango Therapeutics by 12.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,771 shares of the company’s stock valued at $102,000 after acquiring an additional 1,426 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Tango Therapeutics by 8.1% during the second quarter. The Manufacturers Life Insurance Company now owns 29,511 shares of the company’s stock worth $253,000 after purchasing an additional 2,218 shares during the last quarter. SG Americas Securities LLC raised its stake in Tango Therapeutics by 16.0% during the first quarter. SG Americas Securities LLC now owns 30,429 shares of the company’s stock worth $242,000 after purchasing an additional 4,203 shares during the period. Point72 DIFC Ltd acquired a new position in shares of Tango Therapeutics in the 2nd quarter valued at $54,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Tango Therapeutics by 32.6% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,964 shares of the company’s stock valued at $230,000 after buying an additional 7,128 shares during the period. Hedge funds and other institutional investors own 78.99% of the company’s stock.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.